Expansion momentum Pace Analytical has actively expanded through acquisitions and lab capacity investments, including two life sciences laboratories in 2025 and a recent acquisition in 2024, signaling growth potential and cross-sell opportunities into pharmaceutical and biopharma segments.

Regulatory and lab services The company combines analytical testing with regulatory consulting, facility certifications, and instrument services, presenting a broad value proposition for clients seeking end‑to‑end compliance and workflow support across environmental and life sciences labs.

PFAS and silica focus Recent launches and awards around ultrashort-chain PFAS testing and respirable crystalline silica testing indicate strategic capabilities that can address growing regulatory scrutiny and worker safety requirements, offering entry points for EH&S and regulated industry customers.

Life sciences partnerships New collaborations with Aspire Biolabs for drug-excipient compatibility, formulation development, batch manufacturing, and stability studies open doors for deeper lab and analytical support within the pharma development and manufacturing continuum.

Leadership and scale Leadership changes and a clear investment in R&D leadership signal a forward-looking approach, coupled with a scalable, multi-lab network, creating opportunities to position Pace as a reliable partner for large enterprise clients seeking national lab coverage and standardized services.